Immune Checkpoint Inhibitor-induced Pneumonitis: Incidence, Clinical Characteristics, and Outcomes
Background: Immune checkpoint inhibitors (ICIs) are the newest class of anticancer drugs. Pneumonitis is increasingly being recognized as a potential complication of these agents. Methods: We conducted a retrospective study of patients who received ICIs at a comprehensive cancer center. We collected...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Wolters Kluwer Medknow Publications
2023-04-01
|
| Ráidu: | Hematology/Oncology and Stem Cell Therapy |
| Fáttát: | |
| Liŋkkat: | https://journals.lww.com/10.1016/j.hemonc.2021.09.005 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|